RE:Heads Should RollGorf79 ...
Samething happened on this Nov. 8, 2017. The stock price dropped from 0.41$ to 0.17$, for no justified reason, on excellent and easy to decipher news, especially that we now know that the Ph. 1b was terminated early later on because of outstanding data (p#5 and p#6 having been cancer free with only 1 dose). So the current drop has no more justification and it will re-adjust over time. Science is not going away. Theralase Provides Interim Data Analysis on Anti-Cancer Treatment for First Four Patients Treated
November 8, 2017, 7:00 AM EST
Theralase Provides Interim Data Analysis on Anti-Cancer Treatment for First Four Patients Treated First Four Patients Treated with Company’s Anti-Cancer Treatment Achieve Pre-Defined Primary, Secondary and Exploratory Outcome Measures Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer provides an interim data analysis on the first four patients treated, with the Company’s patented, light-activated PDC, TLD-1433, in a Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”), demonstrating successful achievement of the pre-defined primary, secondary and exploratory outcome measures.